Hormone therapy in women with primary ovarian insufficiency or early menopause

Menopause

Volumn 22, Issue 9, 2015, Pages 923-925

  Gatta, Luke A ^a,b   Jiang, Xuezhi ^b,c   Schnatz, Peter F ^b,c  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b READING HOSPITAL AND MEDICAL CENTER   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ESTROGEN; TESTOSTERONE;

CLIMACTERIUM; EARLY MENOPAUSE; FEMALE; HEART INFARCTION; HORMONAL THERAPY; HUMAN; MENOPAUSE; POSTMENOPAUSE; PREMATURE OVARIAN FAILURE; REVIEW; WEIGHT GAIN; OSTEOPOROSIS;

FEMALE; HUMANS; MENOPAUSE; OSTEOPOROSIS; PRIMARY OVARIAN INSUFFICIENCY;

EID: 84983189273     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0000000000000518     Document Type: Review

References (25)

1. Rosenberg L, Hennekens CH, Rosner B, Belanger C, Rothman KJ, Speizer FE. Early menopause and the risk of myocardial infarction. Am J Obstet Gynecol 1981; 139: 47-51
2. Tuppurainen M, Kröger H, Honkanen R, et al. Risks of perimenopausal fractures-A prospective population-based study. Acta Obstet Gynecol Scand 1995; 74: 624-628
3. The North American Menopause Society. Management of osteoporosis in postmenopausal women: 2010 statement of The North American Menopause Society. Menopause 2010; 17: 25-54
4. Clarke BL, Khosla S. Female reproductive system and bone. Arch Biochem Biophys 2010; 503: 118-128
5. Kaunitz AM. Extended duration use of menopausal hormone therapy. Menopause 2014; 21: 679-681
6. Benetti-Pinto CL, Ferreira VB, Yela DA Long-Term follow-up of bone density in women with primary ovarian insufficiency Menopause 2015 22 946-949
7. Popat VB, Calis KA, Kalantaridou SN, et al. Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement. J Clin Endocrinol Metab 2014; 99: 3418-3426
8. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003; 290: 1729-1738
9. Popat VB, Calis KA, Vanderhoof VH, et al. Bone mineral density in estrogen-deficient young women. J Clin Endocrinol Metab 2009; 94: 2277-2283
10. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354: 669-683
11. The North American Menopause Society. The 2012 hormone therapy position statement of The North American Menopause Society. Menopause 2012; 19: 257-271
12. Rafique S, Sterling EW, Lawrence LN. A new approach to primary ovarian insufficiency. Obstet Gynecol Clin North Am 2012; 39: 567-586
13. Rebar RW Premature ovarian failure Obstet Gynecol 2009 113 1355-1363
14. Barrett-Connor E, Young R, Notelovitz M, et al. A two-year, doubleblind comparison of estrogen-Androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles. J Reprod Med 1999; 44: 1012-1020
15. Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333
16. Zuckerman M, Weintraub B, Martin C, Hoggatt J. The hormone replacement therapy market for the treatment of menopausal symptoms in the US. Erial, NJ: inThought Research 2013
17. Clarkson TB, Meléndez GC, Appt SE. The timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future. Menopause 2013; 20: 342-353
18. McGill HC Jr, McMahan CA, Zieske AW, et al. Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. Arterioscler Thromb Vasc Biol 2000; 20: 1998-2004
19. Clarkson TB, Appt SE. Controversies about HRT-lessons from monkey models. Maturitas 2005; 51: 64-74
20. Bairey Merz CN, Johnson BD, Sharaf BL, et al. Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE study. J Am Coll Cardiol 2003; 41: 413-419
21. Schnatz PF. Hormonal therapy: does it increase or decrease cardiovascular risk? Obstet Gynecol Surv 2006; 61: 673-681
22. Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 2007; 69: 1074-1083
23. Maki PM. Critical window hypothesis of hormone therapy and cognition: a scientific update on clinical studies. Menopause 2013; 20: 695-709
24. Sarel PM, Nijike VY, Vinante V, Katz DL. The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years. Am J Public Health 2013; 103: 1583-1588
25. Kaunitz AM, Manson JE. Failure to treat menopausal symptoms: a disconnect between clinical practice and scientific data. Menopause 2015; 22: 687-688